{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Naumenko V"],"funding":["Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre","Canadian Cancer Society Research Institute","CIHR"],"pagination":["1385"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9761050"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["There is debate in the field of oncolytic virus (OV) therapy, whether a single viral dose, or multiple administrations, is better for tumor control. Using intravital microscopy, we describe the fate of vesicular stomatitis virus (VSV) delivered systemically as a first or a second dose. Following primary administration, VSV binds to the endothelium, initiates tumor infection and activates a proinflammatory response. This initial OV dose induces neutrophil migration into the tumor and limits viral replication. OV administered as a second dose fails to infect the tumor and is captured by intravascular monocytes. Despite a lack of direct infection, this second viral dose, in a monocyte-dependent fashion, enhances and sustains infection by the first viral dose, promotes CD8 T cell recruitment, "],"journal":["Communications biology"],"pubmed_title":["Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes."],"pmcid":["PMC9761050"],"funding_grant_id":["#DF-18-5","#420828"],"pubmed_authors":["Mah LK","Kim D","Chekhonin VP","Kaul EK","Tse M","Rajwani J","Rakic A","Mahoney DJ","Naumenko V","Dastidar H","Turk M","Zhang C","Jenne CN","Davis RP","Van S"],"additional_accession":[]},"is_claimable":false,"name":"Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes.","description":"There is debate in the field of oncolytic virus (OV) therapy, whether a single viral dose, or multiple administrations, is better for tumor control. Using intravital microscopy, we describe the fate of vesicular stomatitis virus (VSV) delivered systemically as a first or a second dose. Following primary administration, VSV binds to the endothelium, initiates tumor infection and activates a proinflammatory response. This initial OV dose induces neutrophil migration into the tumor and limits viral replication. OV administered as a second dose fails to infect the tumor and is captured by intravascular monocytes. Despite a lack of direct infection, this second viral dose, in a monocyte-dependent fashion, enhances and sustains infection by the first viral dose, promotes CD8 T cell recruitment, ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-29T04:34:16.544Z","creation":"2025-04-07T01:57:07.704Z"},"accession":"S-EPMC9761050","cross_references":{"pubmed":["36536097"],"doi":["10.1038/s42003-022-04254-3"]}}